| Pharmaceutical Information |
| Drug Name |
Talazoparib |
| Drug ID |
BADD_D02485 |
| Description |
Talazoparib was approved by the FDA for use in germline BRCA mutated, HER2 negative, locally advanced or metastatic breast cancer on October 16, 2018 under the trade name Talzenna [L4661]. Talzenna was granted approval based on the results of the EMBRACA trial in which talazoparib resulted in a mean 8.6 months progression-free survival time versus physician's choice chemotherapy which resulted in 5.6 months progression-free survival. |
| Indications and Usage |
Talazoparib is indicated for the treatment of deleterious or suspected deleterious germline BRCA mutated, HER2 negative locally advanced or metastatic breast cancer in adults [FDA Label]. |
| Marketing Status |
Not Available |
| ATC Code |
L01XK04 |
| DrugBank ID |
DB11760
|
| KEGG ID |
D10732
|
| MeSH ID |
C586365
|
| PubChem ID |
135565082
|
| TTD Drug ID |
D0GV8J
|
| NDC Product Code |
0069-0296; 46014-3130; 46014-3120; 63539-295; 0069-1501; 46014-1140; 0069-1751; 0069-1195 |
| Synonyms |
talazoparib | Talzenna | BMN 673 | BMN-673 | BMN673 |
|
| Chemical Information |
| Molecular Formula |
C19H14F2N6O |
| CAS Registry Number |
1207456-01-6 |
| SMILES |
CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
